A hypersexual paraphilic patient treated with leuprolide acetate: A single case report

Journal of Sex and Marital Therapy

Volumn 31, Issue 5, 2005, Pages 433-444

  Saleh, Fabian ^a,b,c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b National Institute for the Study Prevention and Treatment of Sexual Trauma   (United States)

^c UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTAMIDE; FOLLITROPIN; GONADORELIN AGONIST; LEUPRORELIN; LUTEINIZING HORMONE; TESTOSTERONE;

ADULT; BEHAVIOR THERAPY; CASE REPORT; COGNITIVE THERAPY; EXHIBITIONISM; HORMONE DETERMINATION; HUMAN; LIBIDO; MALE; PENIS; PLETHYSMOGRAPHY; PSYCHOTHERAPY; REVIEW; SELF CONCEPT; SEXUAL DEVIATION; TREATMENT OUTCOME;

ADULT; ANDROGEN ANTAGONISTS; FORENSIC PSYCHIATRY; GONADOTROPIN-RELEASING HORMONE; HUMANS; LEUPROLIDE; MALE; PARAPHILIAS; TREATMENT OUTCOME;

EID: 23944439482     PISSN: 0092623X     EISSN: None     Source Type: Journal    
DOI: 10.1080/00926230591006782     Document Type: Review

References (25)

1. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., rev). Washington, DC: Author.
2. Berlin, F. S., & Meinecke, C. F. (1981). Treatment of sex offenders with antiandrogenic medication: Conceptualization, review of treatment modalities, and preliminary findings. American Journal of Psychiatry, 138, 601-607.
3. Blanchard, R., Klassen, P., Dickey, R., Kuban, M. E., & Blak, T. (2001). Sensitivity and specificity of the phallometric test for pedophilia in nonadmitting sex offenders. Psychological Assessment, 13(1), 118-126.
4. Bradford, J. M., & Pawlak, A. (1993). Double-blind placebo crossover study of cyproterone acetate in the treatment of the paraphilias. Archives of Sexual Behavior, 22, 383-402.
5. Bradford, J. M. W., Greenberg, D., Gojer, J., Martindale, J. J., & Goldberg, M. (1995). Sertraline in the treatment of pedophilia: An open label study. New Research Program Abstracts NR 441: American Psychiatric Association Meeting, May 1995; Miami, Florida.
6. Briken, P., Hill, A., & Berner, W. (2003). Pharmacotherapy of paraphilias with long-acting agonists of luteinizing hormone-releasing hormone: A systematic review. Journal of Clinical Psychiatry, 64, 890-897.
7. Briken, P., Nika, E., & Berner, W. (2001). Treatment of paraphilia with luteinizing hormone-releasing hormone agonists. Journal of Sex & Marital Therapy, 27, 45-55.
8. Cooper, A. J., Cernosvsky, Z., & Magnus, R. V. (1992). The long-term use of cyproterone acetate in pedophilia: A case study. Journal of Sex & Marital Therapy, 18, 292-302.
9. Cooper, A. J., Sandhu, S., Losztyn, S., & Cernovsky, Z. (1992). A double-blind placebo controlled trial of medroxyprogesterone acetate and cyproterone acetate with seven pedophiles. Canadian Journal of Psychiatry, 37, 687-693.
10. Dickey, R. (1992). The management of case of treatment-resistant paraphilia with a long-acting LHRH agonist. Canadian Journal of Psychiatry, 37, 567-569.
11. Dickey, R. (2002). Case report: The management of bone demineralization associated with long-term treatment of multiple paraphilias with long-acting LHRH agonists. Journal of Sex & Marital Therapy, 28:207-210.
12. Gagne, P. (1981). Treatment of sex offenders with medroxyprogesterone acetate. American Journal of Psychiatry, 138, 644-646.
13. Gijs, I., & Gooren, L. (1996). Hormonal and psychopharmacological interventions in the treatment of paraphilias: An update. Journal of Sex Research, 33, 273-290.
14. Gottesman, H. G., & Schubert, D. S. P. (1993). Low-dose oral medroxyprogesterone acetate in the management of the paraphilias. Journal of Clinical Psychiatry, 54, 182-8.
15. Grasswick, L. J. & Bradford, J. M. (2003). Osteoporosis associated with the treatment of paraphilias: A clinical review of seven case reports. Journal of Forensic Sciences, 48, 849-855.
16. Greenberg, D. M., Bradford, J. M. W., Curry, S., & O'Rourke, A. (1996). A comparison of treatment of paraphilias with three serotonin reuptake inhibitors: A retrospective study. Bulletin of the American Academy of Psychiatry and the Law, 24, 525-532.
17. Kafka, M. P. (1994). Sertraline pharmacotherapy for paraphilias and paraphilia-related disorders: An open trial. Annals Clinical Psychiatry, 6, 189-195.
18. Kafka, M. P. (1997). A monoamine hypothesis for the pathophysiology of paraphilic disorders. Archives of Sexual Behavior, 26, 343-358.
19. Kafka, M. P., Prentky, R. (1992). Fluoxetine treatment of non-paraphilic sexual addictions and paraphilias in men. Journal of Clinical Psychiatry, 53, 351-358.
20. Krueger, R. B., & Kaplan, M. S. (2001). Depot-leuprolide acetate for treatment of paraphilias: A report of twelve cases. Archives of Sexual Behavior, 30, 409-422.
21. Meyer, W. J., Cole, C., & Emory, E. (1992). Depo provera treatment for sex offending behavior: An evaluation of outcome. Bulletin of the American Academy of Psychiatry and the Law, 20, 249-259.
22. Saleh, F. M., & Guidry, L. L (2003). Psychosocial and biological treatment considerations for the paraphilic and nonparaphilic sex offender. The Journal of the American Academy of Psychiatry and the Law, 31, 486-493.
23. Saleh, F. M., Niel, T., & Fishman, M. (2004). Treatment of paraphilia in young adults with leuprolide acetate: A preliminary case report series. The Journal of Forensic Sciences, 49(6), 2-6.
24. Vermette, H., & Saleh, F. M. (2004). Sex offenders: Issues in forensic research. American Academy of Psychiatry and the Law Newsletter, 29, 11-12.
25. Walker, P. A., & Meyer, W. J. (1981). Medroxyprogesterone acetate treatment for paraphilic sex offenders. In J. R. Hayes, T. K. Roberts, & K. S. Soloway (Eds.), Violence and the violent individual (pp. 353-373). New York: Spectrum Publications.